The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.